Obsidian Therapeutics, Inc. Common Stock (OBX) — Working Capital to Net Assets Ratio
Obsidian Therapeutics, Inc. Common Stock (OBX) has a Working Capital to Net Assets ratio of -17.7% as of March 2026. Working capital of $48.81 Million (current assets of $64.04 Million minus current liabilities of $15.23 Million) is measured against net assets of $-276.20 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Obsidian Therapeutics, Inc. Common Stock (OBX) defensive interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Obsidian Therapeutics, Inc. Common Stock Working Capital to Net Assets (2024–2025)
This chart shows how Obsidian Therapeutics, Inc. Common Stock's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of March 2026, the ratio stands at -17.7%, reflecting working capital of $48.81 Million against net assets of $-276.20 Million USD. For the complete balance sheet picture, see OBX current and non-current assets.
Annual Working Capital to Net Assets for Obsidian Therapeutics, Inc. Common Stock (2024–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Obsidian Therapeutics, Inc. Common Stock from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check Obsidian Therapeutics, Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -24.9% | $66.15 Million | $-266.04 Million | $81.52 Million | $15.36 Million | ▲ +65.0 pp |
| 2024 | -89.9% | $156.76 Million | $-174.43 Million | $172.85 Million | $16.09 Million | — |